GlassScriptPhysician profile
Shannon E Thompson
NPI 1508827312
$5,032.35
in general payments reported to CMS, 2019-2025
23 companies · $2,472 in 2025
The $2,472 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.26 · 2022: $740 · 2023: $1,057 · 2024: $693 · 2025: $2,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,679 · Travel and Lodging: $1,485 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,678.53 |
| Travel and Lodging | $1,484.80 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,115.48 | 2022-2025 | Minimed 780g |
| Lilly USA, LLC | $605.55 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $297.28 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $276.17 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $264.70 | 2022-2025 | Dexcom G6 Transmitter |
| Sequel Med Tech, LLC | $237.65 | 2025 | Twiist |
| Sanofi-Aventis U.S. LLC | $166.17 | 2022-2024 | |
| Insulet Corporation | $160.44 | 2022-2024 | Omnipod |
| Abbvie INC. | $160.24 | 2021-2023 | |
| Antares Pharma, INC. | $140.20 | 2022-2025 | Xyosted |
| Tolmar, INC. | $101.71 | 2024-2025 | Jatenzo |
| Tandem Diabetes Care, INC. | $89.09 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $75.35 | 2025 | Yorvipath |
| Mannkind Corporation | $75.00 | 2023 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.90 | 2022-2024 | Tradjenta, Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $47.04 | 2023 | |
| Amneal Pharmaceuticals LLC | $38.78 | 2021-2025 | Unithroid |
| Ibsa Pharma INC. | $25.61 | 2022 | |
| Azurity Pharmaceuticals, INC. | $23.70 | 2023 | Edarbyclor |
| Xeris Pharmaceuticals, INC. | $23.13 | 2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $18.73 | 2023 | Steglatro |
| Amgen INC. | $14.98 | 2025 | Tepezza |
| Beta Bionics, INC. | $12.45 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.